Amendment: SEC Form SC 13G/A filed by Trevi Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Trevi Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Trevi Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Trevi Therapeutics Inc.

Recent Analyst Ratings for
$TRVI

Recent Analyst Ratings for
$TRVI

$TRVI
Press Releases

$TRVI
SEC Filings

$TRVI
Analyst Ratings

$TRVI
Insider Trading

$TRVI
Financials

$TRVI
Large Ownership Changes

Crush Q3 2025 with the Best AI Executive Assistant

Crush Q3 2025 with the Best AI Executive Assistant

Fastest customizable press release news feed in the world

Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism

Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock

Trevi Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

SEC Form 8-K filed by Trevi Therapeutics Inc.

SEC Form 424B5 filed by Trevi Therapeutics Inc.

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Cantor Fitzgerald initiated coverage on Trevi Therapeutics with a new price target

H.C. Wainwright initiated coverage on Trevi Therapeutics with a new price target

Trevi Therapeutics upgraded by Raymond James with a new price target

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Mathers Edward T

SEC Form 4 filed by Director Meeker David P

SEC Form 4 filed by Director Vanlent Anne

Live finance-specific insights

Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

This live feed shows all institutional transactions in real time.

11/6/24 10:30:26 AM ET

$TRVI

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $TRVI alert in real time by email

SC 13G/A 1 d869859dsc13ga.htm SC 13G/A SC 13G/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)*

Trevi Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

89532M101

(CUSIP Number)

September 30, 2024

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐

Rule 13d-1(b)

☒

Rule 13d-1(c)

☐

Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 89532M101

(1)

Consists of 5,646,596 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P.

(2)	Based on 72,591,917 shares of Common Stock outstanding on July 31, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on August 8, 2024.

CUSIP No. 89532M101

(1)

(2)	Based on 72,591,917 shares of Common Stock outstanding on July 31, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on August 8, 2024.

CUSIP No. 89532M101

(1)

(2)	Based on 72,591,917 shares of Common Stock outstanding on July 31, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on August 8, 2024.

CUSIP No. 89532M101

(1)

Consists of 391,551 shares of Common Stock held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P.

(2)	Based on 72,591,917 shares of Common Stock outstanding on July 31, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on August 8, 2024.

CUSIP No. 89532M101

(1)

(2)	Based on 72,591,917 shares of Common Stock outstanding on July 31, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on August 8, 2024.

CUSIP No. 89532M101

(1)

(2)	Based on 72,591,917 shares of Common Stock outstanding on July 31, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on August 8, 2024.

CUSIP No. 89532M101

(1)

Consists of 1,342,943 shares of Common Stock held directly by Frazier Life Sciences XI, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P.

(2)	Based on 72,591,917 shares of Common Stock outstanding on July 31, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on August 8, 2024.

CUSIP No. 89532M101

(1)

(2)	Based on 72,591,917 shares of Common Stock outstanding on July 31, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on August 8, 2024.

CUSIP No. 89532M101

(1)

(2)	Based on 72,591,917 shares of Common Stock outstanding on July 31, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on August 8, 2024.

CUSIP No. 89532M101

(1)

Consists of (i) 5,646,596 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P., (ii) 391,551 shares of Common Stock held directly by Frazier Life Sciences X, L.P., and (iii) 1,342,943 shares of Common Stock held directly by Frazier Life Sciences XI, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P.

(2)	Based on 72,591,917 shares of Common Stock outstanding on July 31, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on August 8, 2024.

CUSIP No. 89532M101

(1)

(2)	Based on 72,591,917 shares of Common Stock outstanding on July 31, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on August 8, 2024.

CUSIP No. 89532M101

(1)

(2)	Based on 72,591,917 shares of Common Stock outstanding on July 31, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on August 8, 2024.

CUSIP No. 89532M101

(1)

(2)	Based on 72,591,917 shares of Common Stock outstanding on July 31, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on August 8, 2024.

CUSIP No. 89532M101

(1)

(2)	Based on 72,591,917 shares of Common Stock outstanding on July 31, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on August 8, 2024.

Item 1(a).

Name of Issuer: Trevi Therapeutics, Inc.

Item 1(b).

Address of Issuer’s Principal Executive Offices: 195 Church Street, 14^th Floor, New Haven, Connecticut 06510

Item 2(a).

Name of Person Filing:

The entities and persons filing this statement (collectively, the “Reporting Persons”) are:

Frazier Life Sciences Public Fund, L.P. (“FLSPF”)

FHMLSP, L.P.

FHMLSP, L.L.C.

Frazier Life Sciences X, L.P. (“FLS X”)

FHMLS X, L.P.

FHMLS X, L.L.C.

Frazier Life Sciences XI, L.P. (“FLS XI”)

FHMLS XI, L.P.

FHMLS XI, L.L.C.

James N. Topper (“Topper”)

Patrick J. Heron (“Heron”)

Albert Cha (“Cha”)

James Brush (“Brush”)

Daniel Estes (“Estes” and together with Topper, Heron, Cha and Brush, the “Members”)

Item 2(b).

Address of Principal Business Office or, if none, Residence:

The address and principal business office of the Reporting Persons is:

c/o Frazier Life Sciences Management, L.P.

1001 Page Mill Rd, Building 4, Suite B

Palo Alto, CA 94304

Item 2(c).

Citizenship:


Entities:	FLSPF	-	Delaware, U.S.A.
	FHMLSP, L.P.	-	Delaware, U.S.A.
	FHMLSP, L.L.C.	-	Delaware, U.S.A.
	FLS X	-	Delaware, U.S.A.
	FHMLS X, L.P.	-	Delaware, U.S.A.
	FHMLS X, L.L.C.	-	Delaware, U.S.A.
	FLS XI	-	Delaware, U.S.A.
	FHMLS XI, L.P.	-	Delaware, U.S.A.
	FHMLS XI, L.L.C.	-	Delaware, U.S.A.
Individuals:	Topper	-	United States Citizen
	Heron	-	United States Citizen
	Cha	-	United States Citizen
	Brush	-	United States Citizen
	Estes	-	United States Citizen

Item 2(d).

Title of Class of Securities: Common Stock

Item 2(e).

CUSIP Number: 89532M101

Item 3.

If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:


(a)	☐	Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);

(b)	☐	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)	☐	Insurance company as defined in section 3(a)19) of the Act (15 U.S.C. 78c);

(d)	☐	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);


(e)	☐	An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

(f)	☐	An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

(g)	☐	A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

(h)	☐	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)	☐	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)	☐	A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);

(k)	☐	Group, in accordance with §240.13d–1(b)(1)(ii)(K).

	If filing as a non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J), please specify the type of institution: ____

Item 4.

Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the Issuer identified in Item 1.

(a)

Amount Beneficially Owned: See Row 9 of cover page for each Reporting Person.

(b)

Percent of Class: See Row 11 of cover page for each Reporting Person

(c)

Number of shares as to which the person has:

(i)

Sole power to vote or to direct the vote: See Row 5 of cover page for each Reporting Person.

(ii)

Shared power to vote or to direct the vote: See Row 6 of cover page for each Reporting Person.

(iii)

Sole power to dispose or to direct the disposition of: See Row 7 of cover page for each Reporting Person.

(iv)

Shared power to dispose or to direct the disposition of: See Row 8 of cover page for each Reporting Person.

Item 5.

Ownership of 5 Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.

Item 6.

Ownership of More than 5 Percent on Behalf of Another Person

Not applicable.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

Not applicable.

Item 8.

Identification and Classification of Members of the Group

Each member of the group is identified on Exhibit A to this Schedule 13G.

Item 9.

Notice of Dissolution of a Group

Not applicable.

Item 10.

Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.


Date: November 6, 2024	FRAZIER LIFE SCIENCES PUBLIC FUND, L.P.
	By:	FHMLSP, L.P., its General Partner
	By:	FHMLSP, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: November 6, 2024	FHMLSP, L.P.
	By:	FHMLSP, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: November 6, 2024	FHMLSP, L.L.C.
	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: November 6, 2024	FRAZIER LIFE SCIENCES X, L.P.
	By:	FHMLS X, L.P., its General Partner
	By:	FHMLS X, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: November 6, 2024	FHMLS X, L.P.
	By:	FHMLS X, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: November 6, 2024	FHMLS X, L.L.C.

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: November 6, 2024	FRAZIER LIFE SCIENCES XI, L.P.
	By:	FHMLS XI, L.P., its General Partner
	By:	FHMLS XI, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: November 6, 2024	FHMLS XI, L.P.
	By:	FHMLS XI, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer


Date: November 6, 2024		FHMLS XI, L.L.C.

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: November 6, 2024	By:	*
		James N. Topper

Date: November 6, 2024	By:	*
		Patrick J. Heron

Date: November 6, 2024	By:	**
		Albert Cha

Date: November 6, 2024	By:	**
		James Brush

Date: November 6, 2024	By:	***
		Daniel Estes

Date: November 6, 2024	By:	/s/ Steve R. Bailey
		Steve R. Bailey, as Attorney-in-Fact

*	This Schedule 13G was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on March 29, 2016.

**	This Schedule 13G was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021.

***	This Schedule 13G was executed by Steve R. Bailey on behalf of the individual listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on April 18, 2022.

Get the next $TRVI alert in real time by email

Recent Analyst Ratings for

$TRVI

Date	Price Target	Rating	Analyst
7/1/2025	$25.00	Overweight	Cantor Fitzgerald
5/28/2025	$21.00	Buy	H.C. Wainwright
3/10/2025	$9.00 → $29.00	Outperform → Strong Buy	Raymond James
3/10/2025	$8.00 → $25.00	Buy	Needham
12/12/2024	$6.00 → $7.50	Buy	H.C. Wainwright
9/9/2024	$6.00 → $7.00	Outperform	Leerink Partners
8/30/2024	$6.00	Buy	H.C. Wainwright
8/30/2024	$9.00	Outperform	Raymond James

More analyst ratings

11/6/24 10:30:26 AM ET

$TRVI

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $TRVI alert in real time by email

SC 13G/A 1 d869859dsc13ga.htm SC 13G/A SC 13G/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)*

Trevi Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

89532M101

(CUSIP Number)

September 30, 2024

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐

Rule 13d-1(b)

☒

Rule 13d-1(c)

☐

Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

CUSIP No. 89532M101

(1)

(2)	Based on 72,591,917 shares of Common Stock outstanding on July 31, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on August 8, 2024.

CUSIP No. 89532M101

(1)

(2)	Based on 72,591,917 shares of Common Stock outstanding on July 31, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on August 8, 2024.

CUSIP No. 89532M101

(1)

(2)	Based on 72,591,917 shares of Common Stock outstanding on July 31, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on August 8, 2024.

CUSIP No. 89532M101

(1)

(2)	Based on 72,591,917 shares of Common Stock outstanding on July 31, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on August 8, 2024.

CUSIP No. 89532M101

(1)

(2)	Based on 72,591,917 shares of Common Stock outstanding on July 31, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on August 8, 2024.

CUSIP No. 89532M101

(1)

(2)	Based on 72,591,917 shares of Common Stock outstanding on July 31, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on August 8, 2024.

CUSIP No. 89532M101

(1)

(2)	Based on 72,591,917 shares of Common Stock outstanding on July 31, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on August 8, 2024.

CUSIP No. 89532M101

(1)

(2)	Based on 72,591,917 shares of Common Stock outstanding on July 31, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on August 8, 2024.

CUSIP No. 89532M101

(1)

(2)	Based on 72,591,917 shares of Common Stock outstanding on July 31, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on August 8, 2024.

CUSIP No. 89532M101

(1)

(2)	Based on 72,591,917 shares of Common Stock outstanding on July 31, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on August 8, 2024.

CUSIP No. 89532M101

(1)

(2)	Based on 72,591,917 shares of Common Stock outstanding on July 31, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on August 8, 2024.

CUSIP No. 89532M101

(1)

(2)	Based on 72,591,917 shares of Common Stock outstanding on July 31, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on August 8, 2024.

CUSIP No. 89532M101

(1)

(2)	Based on 72,591,917 shares of Common Stock outstanding on July 31, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on August 8, 2024.

CUSIP No. 89532M101

(1)

(2)	Based on 72,591,917 shares of Common Stock outstanding on July 31, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on August 8, 2024.

Item 1(a).

Name of Issuer: Trevi Therapeutics, Inc.

Item 1(b).

Address of Issuer’s Principal Executive Offices: 195 Church Street, 14^th Floor, New Haven, Connecticut 06510

Item 2(a).

Name of Person Filing:

The entities and persons filing this statement (collectively, the “Reporting Persons”) are:

Frazier Life Sciences Public Fund, L.P. (“FLSPF”)

FHMLSP, L.P.

FHMLSP, L.L.C.

Frazier Life Sciences X, L.P. (“FLS X”)

FHMLS X, L.P.

FHMLS X, L.L.C.

Frazier Life Sciences XI, L.P. (“FLS XI”)

FHMLS XI, L.P.

FHMLS XI, L.L.C.

James N. Topper (“Topper”)

Patrick J. Heron (“Heron”)

Albert Cha (“Cha”)

James Brush (“Brush”)

Daniel Estes (“Estes” and together with Topper, Heron, Cha and Brush, the “Members”)

Item 2(b).

Address of Principal Business Office or, if none, Residence:

The address and principal business office of the Reporting Persons is:

c/o Frazier Life Sciences Management, L.P.

1001 Page Mill Rd, Building 4, Suite B

Palo Alto, CA 94304

Item 2(c).

Citizenship:


Entities:	FLSPF	-	Delaware, U.S.A.
	FHMLSP, L.P.	-	Delaware, U.S.A.
	FHMLSP, L.L.C.	-	Delaware, U.S.A.
	FLS X	-	Delaware, U.S.A.
	FHMLS X, L.P.	-	Delaware, U.S.A.
	FHMLS X, L.L.C.	-	Delaware, U.S.A.
	FLS XI	-	Delaware, U.S.A.
	FHMLS XI, L.P.	-	Delaware, U.S.A.
	FHMLS XI, L.L.C.	-	Delaware, U.S.A.
Individuals:	Topper	-	United States Citizen
	Heron	-	United States Citizen
	Cha	-	United States Citizen
	Brush	-	United States Citizen
	Estes	-	United States Citizen

Item 2(d).

Title of Class of Securities: Common Stock

Item 2(e).

CUSIP Number: 89532M101

Item 3.

If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:


(a)	☐	Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);

(b)	☐	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)	☐	Insurance company as defined in section 3(a)19) of the Act (15 U.S.C. 78c);

(d)	☐	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);


(e)	☐	An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

(f)	☐	An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

(g)	☐	A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

(h)	☐	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)	☐	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)	☐	A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);

(k)	☐	Group, in accordance with §240.13d–1(b)(1)(ii)(K).

	If filing as a non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J), please specify the type of institution: ____

Item 4.

Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the Issuer identified in Item 1.

(a)

Amount Beneficially Owned: See Row 9 of cover page for each Reporting Person.

(b)

Percent of Class: See Row 11 of cover page for each Reporting Person

(c)

Number of shares as to which the person has:

(i)

Sole power to vote or to direct the vote: See Row 5 of cover page for each Reporting Person.

(ii)

Shared power to vote or to direct the vote: See Row 6 of cover page for each Reporting Person.

(iii)

Sole power to dispose or to direct the disposition of: See Row 7 of cover page for each Reporting Person.

(iv)

Shared power to dispose or to direct the disposition of: See Row 8 of cover page for each Reporting Person.

Item 5.

Ownership of 5 Percent or Less of a Class

Item 6.

Ownership of More than 5 Percent on Behalf of Another Person

Not applicable.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

Not applicable.

Item 8.

Identification and Classification of Members of the Group

Each member of the group is identified on Exhibit A to this Schedule 13G.

Item 9.

Notice of Dissolution of a Group

Not applicable.

Item 10.

Certification

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.


Date: November 6, 2024	FRAZIER LIFE SCIENCES PUBLIC FUND, L.P.
	By:	FHMLSP, L.P., its General Partner
	By:	FHMLSP, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: November 6, 2024	FHMLSP, L.P.
	By:	FHMLSP, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: November 6, 2024	FHMLSP, L.L.C.
	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: November 6, 2024	FRAZIER LIFE SCIENCES X, L.P.
	By:	FHMLS X, L.P., its General Partner
	By:	FHMLS X, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: November 6, 2024	FHMLS X, L.P.
	By:	FHMLS X, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: November 6, 2024	FHMLS X, L.L.C.

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: November 6, 2024	FRAZIER LIFE SCIENCES XI, L.P.
	By:	FHMLS XI, L.P., its General Partner
	By:	FHMLS XI, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: November 6, 2024	FHMLS XI, L.P.
	By:	FHMLS XI, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer


Date: November 6, 2024		FHMLS XI, L.L.C.

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: November 6, 2024	By:	*
		James N. Topper

Date: November 6, 2024	By:	*
		Patrick J. Heron

Date: November 6, 2024	By:	**
		Albert Cha

Date: November 6, 2024	By:	**
		James Brush

Date: November 6, 2024	By:	***
		Daniel Estes

Date: November 6, 2024	By:	/s/ Steve R. Bailey
		Steve R. Bailey, as Attorney-in-Fact

*	This Schedule 13G was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on March 29, 2016.

**	This Schedule 13G was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021.

***	This Schedule 13G was executed by Steve R. Bailey on behalf of the individual listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on April 18, 2022.

Get the next $TRVI alert in real time by email

Recent Analyst Ratings for

$TRVI

Date	Price Target	Rating	Analyst
7/1/2025	$25.00	Overweight	Cantor Fitzgerald
5/28/2025	$21.00	Buy	H.C. Wainwright
3/10/2025	$9.00 → $29.00	Outperform → Strong Buy	Raymond James
3/10/2025	$8.00 → $25.00	Buy	Needham
12/12/2024	$6.00 → $7.50	Buy	H.C. Wainwright
9/9/2024	$6.00 → $7.00	Outperform	Leerink Partners
8/30/2024	$6.00	Buy	H.C. Wainwright
8/30/2024	$9.00	Outperform	Raymond James

More analyst ratings

Names of Reporting Persons

Frazier Life Sciences Public Fund, L.P.

Check the Appropriate Box if a Member of a Group (see instructions)

(a) ☐ (b) ☒

SEC USE ONLY

Citizenship or Place of Organization

Delaware